Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

This Helps, Yet It Is Underused in Some with NLPHL

Clin Lymphoma Myeloma Leuk; ePub 2017 Sep 22; Bismarck, et al

Radiotherapy (RT) is linked with longer overall survival in patients with any stage of nodular lymphocytic predominant Hodgkin lymphoma (NLPHL), according to a study involving nearly 2,000 individuals. Still, it is less likely to be used in those who are in an advanced-stage and have B-symptoms. Participants were a median 46 years of age and were diagnosed with NLPHL between 2004 and 2012. Investigators looked at overall survival and survival differences between treatment groups. Among the results:

  • Increasing age, black race, Medicare insurance, chemotherapy use, stage II-IV disease, and presence of B-symptoms predicted RT omission.
  • Overall, patients receiving RT survived ~50 months, vs ~42 months for those who didn’t receive such, even after multivariate analysis.
  • Patients with B symptoms who received RT survived an average of 49 months, vs ~43 months for those who didn’t receive such.


Bismarck O, Boothe D, Frandsen J, Poppe M, Gaffney D. The role of radiation in all stages of nodular lymphocytic predominant Hodgkin lymphoma. [Published online ahead of print September 22, 2017]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2017.09.013.

This Week's Must Reads

FDA postmarketing requirements, Nabhan C et al. JAMA Oncol. 2018 May 10. doi:10.1001/jamaoncol.2018.0610.

Upswing in childhood lymphomas, Siegel DA et al. ASPHO 2018, Abstract 605.

Dapagliflozin suppresses hepcidin, Ghanim HA et al. AACE 2018, Abstract 228.

Methotrexate or nelarabine plus chemo in pediatric T-ALL or T-L, Dunsmore KP et al. ASCO 2018, Abstract 10500.

Blood type is diarrhea destiny, Kumar P et al. J Clin Invest. 2018 May 17; doi: 10.1172/JCI97659.